Roche Gains Majority Stake In Foundation Medicine With R&D, Commercial Partnership
This article was originally published in The Gray Sheet
Executive Summary
Roche is investing up to $1.18 billion in the genomic analysis firm, inking a partnership focused on companion diagnostics, cancer drug development and expanded marketing of Foundation's novel sequencing-based platform.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q1 2015
Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.
Foundation Medicine Seeks "Go-To" Companion Diagnostic Status For Sequencing Test
The firm is barely more than a year old, but Cambridge, Mass.-based Foundation Medicine has set its sights on offering a one-stop companion diagnostic for cancer treatments using next-generation genome sequencing.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”